查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594439

新抗原标靶治疗治疗市场：按目标疾病、新抗原类型、免疫治疗类型、给药途径途径- 全球预测 2025-2030

Neoantigen Targeted Therapies Market by Target Disease Indication, Neoantigens Type, Immunotherapy Type, Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

新抗原标靶治疗治疗市场2023年估值为33.1亿美元，预计2024年将达45.8亿美元，复合年增长率为38.52%，预计到2030年将达到324.1亿美元。

新抗原标靶治疗专注于利用因肿瘤特异性突变而在癌细胞中特异性表达的新抗原来创建个人化癌症疫苗和过继性 T 细胞疗法。对这些治疗方法的需求是巨大的，因为与传统疗法相比，它们有可能减少脱靶效应并提高特异性和疗效。治疗方法适用于个人化医疗，并根据基因图谱为每位患者量身定制。最终用途包括医院、癌症研究中心和从事大规模临床应用的製药公司。影响该市场的主要成长要素包括癌症盛行率的增加、基因组技术的进步以及个人化医疗投资的增加。越来越多地采用次世代定序和生物资讯工具来增强新抗原的识别，这是一个重大的商机。製药公司和研究机构应注重策略合作，有效利用生物资讯能力和基因组资料库来优化新抗原的预测和检验。然而，治疗成本上升、新抗原识别的复杂性以及严格的法律规范等挑战可能会阻碍市场成长。克服这些障碍需要创新，特别是在自动化生物资讯分析和具有成本效益的生产技术方面，以提高可及性。对高度自适应人工智慧/机器学习模型的投资可以彻底改变新抗原的发现过程，从而实现更快、更准确的预测并推动市场发展势头。这个市场的本质是高度动态的，受到快速的技术进步和不断变化的监管环境的推动。相关人员应专注于产生可靠的临床试验和真实世界证据，以证明治疗的有效性和安全性，同时遵守国际监管标准。基因组研究的持续创新，加上精准肿瘤学的策略定位，为公司提供了成长途径。生技公司、医疗保健提供者和监管机构之间的合作网络可以促进简化开发途径并加快向患者提供突破性治疗方法。

主要市场统计
基准年[2023] 33.1亿美元
预测年份 [2024] 45.8亿美元
预测年份 [2030] 324.1亿美元
复合年增长率（%） 38.52%

市场动态：快速发展的新抗原标靶治疗市场的关键市场洞察

新抗原标靶治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 新抗原标靶治疗越来越受欢迎
    • 癌症患者急剧增加
    • 世界老年人口的增加
    • 医疗基础建设发展
  • 市场限制因素
    • 与新抗原标靶治疗药物相关的副作用
  • 市场机会
    • 癌症治疗的技术进步
    • 加大赎回制度等政府投入
  • 市场挑战
    • 新抗原鑑定的挑战

波特五力：引领新抗原标靶治疗治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解新抗原标靶治疗治疗市场的外部影响

外部宏观环境因素在塑造新抗原标靶治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解新抗原标靶治疗药物市场的竞争状况

对新抗原标靶治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵新抗原标靶治疗治疗市场供应商的绩效评估

FPNV定位矩阵是评估新抗原标靶治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘新抗原标靶治疗市场的成功之路

新抗原标靶治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 新抗原标靶治疗越来越受欢迎
      • 癌症患者数量迅速增加
      • 世界各地老年人口不断增长
      • 发展医疗保健基础设施
    • 抑制因素
      • 与新抗原标靶治疗相关的副作用
    • 机会
      • 癌症治疗的技术进步
      • 增加政府投资，包括赎回计划
    • 任务
      • 新抗原鑑定的挑战
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章以目标疾病适应症分類的新抗原标标靶治疗治疗市场

  • 骨癌
  • 大肠直肠癌
  • 妇科癌症
  • 非小细胞肺癌
  • 肾臟细胞癌

第七章新抗原标靶治疗药物市场（以新抗原类型划分）

  • 现成的新抗原
  • 个人化新抗原

第八章以免疫治疗类型分類的新抗原标靶治疗治疗市场

  • 树突细胞疫苗
  • 基于 DNA/RNA 的疫苗
  • 蛋白质/胜胜肽疫苗
  • 基于 TIL 的治疗方法

第九章新抗原标靶治疗治疗市场：依给药途径

  • 皮内
  • 静脉
  • 皮下的

第十章美洲新抗原标靶治疗治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区新抗原标靶治疗治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲新抗原标靶治疗治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Achilles Therapeutics PLC
  • Advaxis, Inc.
  • Bavarian Nordic
  • BioNTech SE
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genocea Biosciences, Inc.
  • Gradalis, Inc.
  • Gritstone bio, Inc.
  • IOVANCE Biotherapeutics, Inc.
  • ISA Pharmaceuticals BV
  • Medigene AG
  • Merck & Co., Inc.
  • Precision Biologics
Product Code: MRR-43078BB92C77

The Neoantigen Targeted Therapies Market was valued at USD 3.31 billion in 2023, expected to reach USD 4.58 billion in 2024, and is projected to grow at a CAGR of 38.52%, to USD 32.41 billion by 2030.

Neoantigen-targeted therapies focus on creating personalized cancer vaccines and adoptive T cell therapies by exploiting neoantigens, which are unique to cancer cells due to tumor-specific mutations. These therapies hold immense necessity as they offer the potential for enhanced specificity and effectiveness with reduced off-target effects compared to traditional treatments. Application spans personalized medicine, where treatments are tailored to individual patients based on genetic profiling. End-use sectors include hospitals, cancer research centers, and pharmaceutical companies working towards large-scale clinical applications. Key growth factors influencing this market include the increasing prevalence of cancer, advancements in genomic technologies, and heightened investments in personalized medicine. The rising adoption of next-generation sequencing and bioinformatics tools enhances neoantigen identification, representing significant opportunities. Pharmaceutical companies and research institutions should focus on strategic collaborations to harness bioinformatics capabilities and genomic databases effectively, optimizing neoantigen prediction and validation. However, challenges such as the high cost of therapies, complexity in neoantigen identification, and stringent regulatory frameworks could impede market growth. Overcoming these barriers necessitates innovation particularly in automated bioinformatics analysis and cost-effective production techniques to enhance accessibility. Investment in adaptive AI/machine learning models could revolutionize neoantigen discovery processes, allowing for faster and more accurate predictions, propelling market momentum. The nature of this market is highly dynamic, driven by rapid technological advancements and evolving regulatory landscapes. Stakeholders should emphasize robust clinical trials and real-world evidence generation to substantiate therapy efficacy and safety while remaining compliant with international regulatory standards. Constant innovation in genomic research, coupled with strategic positioning within precision oncology, offers businesses an avenue for growth. Collaborative networks between biotech firms, healthcare providers, and regulatory bodies can facilitate a streamlined developmental pathway and expedite the provision of these groundbreaking therapies to patients, thus capturing a larger market share in this emergent therapeutic frontier.

KEY MARKET STATISTICS
Base Year [2023] USD 3.31 billion
Estimated Year [2024] USD 4.58 billion
Forecast Year [2030] USD 32.41 billion
CAGR (%) 38.52%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neoantigen Targeted Therapies Market

The Neoantigen Targeted Therapies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the popularity of neoantigen targeted therapies
    • Surge in number of cancer patients
    • Increase in the geriatric population across the globe
    • Developing healthcare infrastructure
  • Market Restraints
    • Side effects associated with neoantigen targeted therapies
  • Market Opportunities
    • Technological advancement in the cancer treatment
    • Increasing government investment such as reimbursement plan
  • Market Challenges
    • Challenges of neoantigen identification

Porter's Five Forces: A Strategic Tool for Navigating the Neoantigen Targeted Therapies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neoantigen Targeted Therapies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neoantigen Targeted Therapies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neoantigen Targeted Therapies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neoantigen Targeted Therapies Market

A detailed market share analysis in the Neoantigen Targeted Therapies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neoantigen Targeted Therapies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neoantigen Targeted Therapies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neoantigen Targeted Therapies Market

A strategic analysis of the Neoantigen Targeted Therapies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neoantigen Targeted Therapies Market, highlighting leading vendors and their innovative profiles. These include Achilles Therapeutics PLC, Advaxis, Inc., Bavarian Nordic, BioNTech SE, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genocea Biosciences, Inc., Gradalis, Inc., Gritstone bio, Inc., IOVANCE Biotherapeutics, Inc., ISA Pharmaceuticals B.V., Medigene AG, Merck & Co., Inc., and Precision Biologics.

Market Segmentation & Coverage

This research report categorizes the Neoantigen Targeted Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Target Disease Indication, market is studied across Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, and Renal Cell Carcinoma.
  • Based on Neoantigens Type, market is studied across Off-the-Shelf Neoantigens and Personalized Neoantigens.
  • Based on Immunotherapy Type, market is studied across Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, and TIL-Based Therapies.
  • Based on Route of Administration, market is studied across Intradermal, Intravenous, and Subcutaneous.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the popularity of neoantigen targeted therapies
      • 5.1.1.2. Surge in number of cancer patients
      • 5.1.1.3. Increase in the geriatric population across the globe
      • 5.1.1.4. Developing healthcare infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with neoantigen targeted therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in the cancer treatment
      • 5.1.3.2. Increasing government investment such as reimbursement plan
    • 5.1.4. Challenges
      • 5.1.4.1. Challenges of neoantigen identification
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neoantigen Targeted Therapies Market, by Target Disease Indication

  • 6.1. Introduction
  • 6.2. Bone Cancer
  • 6.3. Colorectal Cancer
  • 6.4. Gynecological Cancer
  • 6.5. Non-Small Cell Lung Cancer
  • 6.6. Renal Cell Carcinoma

7. Neoantigen Targeted Therapies Market, by Neoantigens Type

  • 7.1. Introduction
  • 7.2. Off-the-Shelf Neoantigens
  • 7.3. Personalized Neoantigens

8. Neoantigen Targeted Therapies Market, by Immunotherapy Type

  • 8.1. Introduction
  • 8.2. Dendritic Cell Vaccines
  • 8.3. DNA / RNA-Based Vaccines
  • 8.4. Protein / Peptide-based Vaccines
  • 8.5. TIL-Based Therapies

9. Neoantigen Targeted Therapies Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Intradermal
  • 9.3. Intravenous
  • 9.4. Subcutaneous

10. Americas Neoantigen Targeted Therapies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Neoantigen Targeted Therapies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Neoantigen Targeted Therapies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Achilles Therapeutics PLC
  • 2. Advaxis, Inc.
  • 3. Bavarian Nordic
  • 4. BioNTech SE
  • 5. Eli Lilly and Company
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Genocea Biosciences, Inc.
  • 8. Gradalis, Inc.
  • 9. Gritstone bio, Inc.
  • 10. IOVANCE Biotherapeutics, Inc.
  • 11. ISA Pharmaceuticals B.V.
  • 12. Medigene AG
  • 13. Merck & Co., Inc.
  • 14. Precision Biologics

LIST OF FIGURES

  • FIGURE 1. NEOANTIGEN TARGETED THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 2. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEOANTIGEN TARGETED THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEOANTIGEN TARGETED THERAPIES MARKET DYNAMICS
  • TABLE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY OFF-THE-SHELF NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA / RNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PROTEIN / PEPTIDE-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TIL-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023